Figitumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Figitumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIGF-1 receptor
Clinical data
ATC code
  • none
Legal status
Legal status
  • Experimental
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6462H9948N1736O2020S54
Molar mass146008.04 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC).[3]

This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]

Anti-cancer mechanism

[edit | edit source]

See Insulin-like growth factor 1 receptor role in cancer.

Clinical trials

[edit | edit source]

The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[5] but others continued.[6][7]

It was to have been included in the I-SPY2 breast cancer trial.[8]

References

[edit | edit source]
  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
  7. ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
  8. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).